Drug-Eluting Bead scientific presentations and abstracts scheduled for CIRSE 2007

23/08/2007

Biocompatibles International plc (LSE: BII), a medical technology company focused on drug-device Combination Products principally for use in oncology, today announced the schedule of scientific presentations and abstracts relating to its Drug-Eluting Bead products at the 2007 meeting of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE), to be held 8-12th September 2007, in Athens, Greece. The schedule is as follows:

  • Dr. Camillo Aliberti, Delta Hospital Ferrara, Italy – “TACE with Drug-Eluting Beads preloaded with irinotecan of liver metastases from colorectal cancer”.
  • Dr Camillo Aliberti, Delta Hospital Ferrara; Professor Giammaria Fiorentini, San Giuseppe General Hospital, Italy – “Drug-Eluting Bead with Irinotecan (DEBIRI) Therapy in colorectal cancer”.
  • Professor Katerina Malagari, University of Athens, Greece - “New approaches in the intra-arterial therapy of hepatocellular carcinoma (HCC)”.
  • Professor Johannes Lammer, University of Vienna, Austria - “Baseline data for PRECISION V, a randomised controlled trial for the use of Drug-Eluting Beads in HCC”.
  • Professor Riccardo Lencioni, University of Pisa, Italy - “Radiofrequency ablation combined with Doxorubicin-Eluting Beads in arterial chemoembolisation of HCC.”
  • Dr Thierry DeBaere, Institute Gustave Roussy, Paris, France – “Ablation combined with intra-arterial injection of Drug-Eluting Beads in the treatment of large hypovascular hepatic metastases”.
  • Dr Claudio Vignali, University of Pisa, Italy – “Preliminary results of transarterial chemoembolisation with Drug-Eluting Beads (PRECISION TACE): comparison with conventional TACE.”
  • Dr Marlo Bezzi, University of Rome, La Sapienza, Italy – “Arterial chemoembolisation with Drug-Eluting Beads for hepatocellular carcinoma; technical aspects, safety and short term results.”
  • Dr Diane Reyes, The Johns Hopkins University, Baltimore, United States – “Intra-arterial Drug-Eluting Beads for patients with unresectable hepatocellular carcinoma: a pilot study”.
  • Dr Julien Namur, Centre for Research in Interventional Imaging, Lariboisiere Hospital, Paris, France – “Reservoir function of Ibuprofen-Eluting Beads: quantification in sheep uterine model”.

Crispin Simon, Chief Executive of Biocompatibles said “We are delighted with the interest shown in our Drug-Eluting Bead technology by some of Europe’s most respected investigators.”

-Ends-

Contact us